Skip to main content
AEMD logo

AEMD · Aethlon Medical Inc · Documents

Track AEMD — free
$4.84 -0.27 (-5.28%) Play latest call Q3 2026 earnings call transcript
Market Cap
$7.78M
Shares
1.61M
Volume · Nov 19 20.26K Avg daily vol (3M) 2.52M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2026 Net loss $7.15M 10-K filed Jun 10, 2026 Quarterly report New FY2027 Q2 Net loss $2.62M 10-Q filed Nov 12, 2026 Latest results New Proposed merger drives workforce reductions and higher expenses 8-K filed Nov 12, 2026 Earnings call Q3 2026 earnings call Held Feb 12, 2026
2026
Nov 16
Current report 8-K
North Immunology updates investor presentation for pending Aethlon merger

Aethlon Medical furnished an updated investor presentation from North Immunology, its merger target under the September 17, 2026 agreement. It details the NOR-101 IL-13 x IL-18 bispecific antibody, Phase 1a start in Q1 2027, and an anticipated $180M private placement.

Regulation FD disclosure
5 source passages
on September 17, 2026, Aethlon Medical, Inc., a Nevada corporation (the “Company”), Nighthawk Merger Sub Corp. On November 16, 2026, North Immunology updated information reflected in an investor presentation NOR - 101 is a Half - life Extended Anti - IL - 13 x IL - 18 Bispecific Antibody Target Phase 1a Start: Q1 2027 Anticipated $180M PIPE raise provides cash into 2H 2028 Open the document at this passage
Nov 12
Quarterly report 10-Q FY2027 Q2, ended Sep 30
North Immunology merger expected in first calendar quarter 2027

Aethlon Medical agreed to merge with North Immunology, a two-step transaction expected to close in first calendar quarter 2027. The six-month net loss rose to $4,165,000, while cash was $6,486,639 as of September 30, 2026.

Net loss $2.62M Diluted EPS -$2.60
Read from the MD&A section
4 source passages
On September 17, 2026, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with North Immunology, Inc. (“North Immunology”) and two wholly owned subsidiaries of the Company, pursuant to which the parties agreed to effect a two-step merger transaction (the “Merger”). The Merger is currently expected to close in the first calendar quarter 2027, subject to required stockholder approvals, completion of the contemplated financing, effectiveness of the applicable registration statement, approval of the combined company’s Nasdaq listing application and satisfaction of other closing conditions. As a result of the changes in expenses noted above, our net loss increased from approximately $3,249,000 in the six months ended September 30, 2025, to $4,165,000 in the six months ended September 30, 2026. As of September 30, 2026, we had a cash balance of $6,486,639 and working capital of $5,582,635. Open the document at this passage
Nov 12
Current report 8-K
Proposed merger drives workforce reductions and higher expenses

Aethlon Medical entered a merger agreement with North Immunology on September 17, 2026 and implemented workforce reductions. Cash was approximately $6.5 million as of September 30, 2026; quarterly operating expenses rose 77.2% to approximately $2.7 million.

Financial results, Regulation FD disclosure
4 source passages
On September 17, 2026, we entered into a Plan of Merger and Reorganization (the “Merger Agreement”) with North Immunology, Inc. (“North Immunology”) and two wholly owned subsidiaries of the Company, pursuant to which the parties agreed to effect a two-step merger transaction (the “Merger”). In connection with the proposed Merger we implemented workforce reductions near the end of the second fiscal quarter. Cash and cash equivalents were approximately $6.5 million as of September 30, 2026. Consolidated operating expenses for quarter increased 77.2% to approximately $2.7 million versus approximately $1.5 million in the prior-year quarter. Open the document at this passage
Oct 9
Current report 8-K Events of Oct 7
Charter or bylaw amendment, or fiscal year change

Aethlon Medical, Inc. increased authorized common stock from 20,000,000 shares to 200,000,000 shares, following stockholder approval on October 1, 2026; the amendment became effective on October 7, 2026.

Oct 5
Current report 8-K/A Events of Oct 1
Shareholder vote results

Aethlon Medical, Inc. stockholders did not approve a proposal to authorize 20,000,000 preferred shares because 204,122 votes in favor fell below the required 355,569; the Articles of Incorporation were not amended.

Oct 1
Current report 8-K
Director or officer change, or executive pay, Shareholder vote results

On October 1, 2026, Aethlon Medical stockholders elected five directors and approved increasing authorized common shares from 20,000,000 to 200,000,000, authorizing 20,000,000 preferred shares, and adding 100,000 shares to its 2020 Equity Incentive Plan.

Read from the first part of this long document
Sep 1
Proxy statement DEF 14A Meeting Oct 1, 2026
Proxy statement AI summary on its way
Aug 31
Current report 8-K Events of Aug 28
Other events AI summary on its way
Aug 21
Proxy statement PRE 14A Meeting Oct 1, 2026
Proxy statement AI summary on its way
Jun 10
Annual report 10-K FY2026, ended Mar 31
Annual report for FY2026 AI summary on its way
Net loss $7.15M Diluted EPS -$10.61
Jun 4
Current report 8-K
Other events AI summary on its way
Mar 17
Current report 8-K Events of Mar 16
Other events AI summary on its way
Jan 16
Proxy statement DEF 14A Meeting Feb 19, 2026
Proxy statement AI summary on its way
2025
Showing 1–50 of 176 documents
Key facts CIK 882291 CUSIP 00808Y703 13F (30d) 16 filings 16 filers Visit website Investor relations